We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...
At Ellutia, we understand that managing Electron Capture Detectors (ECDs) is a complex and critical responsibility for ...
The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...
Cadwalader’s Martin Weinstein says that weakening Foreign Corrupt Practices Act enforcement removes a shield for ethical US ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...
The new policy reverses a Biden administration initiative that asked the government to weigh a company’s internal diversity ...
The Trump administration’s antitrust enforcers will follow Biden-era merger review rules, disappointing critics who had hoped ...
The Trump administration has taken another step to centralize the executive branch with a new order that “reins in ...
Antitrust regulators under Trump keep Biden-era merger guidelines, emphasizing stability for businesses, courts, and ...
The federal agencies responsible for implementing the No Surprises Act (NSA) independent dispute resolution (IDR) process previously notified certified IDR entities that they are permitted to consider ...
The Trump administration is tearing down both regulations and the federal government that enforces them. The consequences will be enormous.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback